查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1980613

骨科生技药品市场规模、份额、成长及全球产业分析：按类型、应用和地区划分，并预测至2026-2034年

Orthobiologics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 181 Pages | 商品交期: 请询问到货日

价格

骨科生技药品市场成长要素

全球骨科生技药品市场正经历显着成长，其主要驱动因素包括骨骼和肌肉骨骼疾病盛行率的上升、整形外科损伤病例的增加以及再生医学的日益普及。该市场在2025年的估值为97亿美元，预计2026年将达到102.2亿美元，到2034年将成长至150.6亿美元，预测期内复合年增长率（CAGR）为5.00%。北美地区在2025年占据市场主导地位，市占率高达47.69%。这主要归功于生物製药在骨骼相关创伤治疗中的快速应用、庞大的患者群体以及大量的整形外科手术。

骨科生技药品是由人体内天然存在的物质製成的产品，用于促进骨骼、韧带、肌腱和肌肉的癒合。它们广泛应用于整形外科手术中，用于修復骨缺损和促进组织再生。干细胞移植和其他生技药品在整形外科治疗中日益广泛的应用预计将进一步推动市场成长。

新冠疫情期间，由于患者就诊量减少、医疗资源重新分配以及供应链中断，市场经历了短暂下滑。 2020年市场收入下降了10.6%，但随着患者数量的增加、疫苗接种率的提高以及整形外科手术的恢復，市场在2021年开始復苏。到2022年，市场已恢復到疫情前的水准。强生服务公司（Johnson & Johnson Services, Inc.）的业绩是最好的例证，该公司报告的净销售额为949.43亿美元，其中整形外科产品贡献显着。

市场趋势

推动市场发展的主要趋势之一是越来越多地使用黏弹性移植物来延缓全膝关节置换术。黏弹性移植物能够恢復滑液的流变特性，减轻疼痛，改善关节功能，并促进软骨再生。研究表明，注射透明质酸治疗可以将全膝关节置换术的等待时间延迟一年以上，这促使黏弹性移植物的应用日益广泛。

市场驱动因素

整形外科损伤、骨折、骨质疏鬆症和运动相关创伤的发生率不断上升，推动了对生物製药的需求。光是在美国，每年就有超过680万名患者寻求整形外科损伤治疗。髋部和脊椎骨折的日益增加以及交通事故的增加，也促进了市场扩张。

另一个因素是新型骨科生物製品的推出，例如同种异体移植材料、骨生长因子和合成骨替代品。例如，Royal Biologics公司于2020年推出了不含DMSO的生物细胞同种异体移植材料MAGNUS，而Biocomposites公司的抗生素缓释骨缺损填充材获得了CE认证。持续的产品创新确保了骨骼修復领域先进解决方案的供应，从而推动了市场成长。

市场限制因素

由于某些骨科生技药品的临床限制以及骨形成蛋白（BMP）相关问题，市场面临许多限制因素。Medtronic的INFUSE是一种广泛使用的BMP，据报其具有严重的副作用，包括感染疾病、泌尿系统疾病、骨骼和神经损伤以及潜在的致癌风险。其他骨科生技药品也因组织排斥、骨形成不全和软组织感染疾病等问题而难以广泛应用。

市场区隔

依产品类型

  • 预计到 2026 年，黏弹性栓剂将占据 31.51% 的市场份额，这主要归因于人口老化导致膝骨关节炎盛行率不断上升。
  • 合成骨替代品预计将实现最高的复合年增长率，这主要得益于已开发地区采用率的提高以及对新产品推出的重视。
  • 由于脱钙骨基质（DBM）和细胞同种异体移植材料具有良好的成骨性和微创应用的特点，它们也为市场做出了重大贡献。

透过使用

  • 预计到 2026 年，脊椎融合手术将以 31.12% 的市场份额引领市场，这主要得益于全球脊椎手术数量的增加以及新的骨科生技药品的核准。
  • 骨折和骨质疏鬆症的日益普遍，使得重组和骨折手术成为第二大市场。

最终用户

  • 到 2026 年，医院和门诊手术中心 (ASC) 将占据市场主导地位，占市场份额的 61.35%，这主要得益于其庞大的患者数量和大量的整形外科手术。
  • 整形外科治疗领域对专业护理的需求日益增长，预计将导致专业诊所的显着增长。

区域趋势

  • 北美：预计到 2025 年市场规模将达到 46.3 亿美元，到 2026 年将达到 45.1 亿美元。这主要得益于大规模的患者群体和先进的医疗保健基础设施。
  • 欧洲：作为第二大市场，在研发投资和积极的临床试验结果的支持下，预计到 2026 年，德国市场规模将达到 7.5 亿美元，英国规模将达到 5.3 亿美元。
  • 亚太地区：由于骨科生技药品渗透率低、患者群体庞大以及骨骼疾病盛行率不断上升，预计该地区将实现最高的复合年增长率。到2026年，日本、中国和印度的市场规模预计将分别达到7.2亿美元、5.5亿美元和3亿美元。
  • 拉丁美洲、中东和非洲：由于人们意识的提高、新生物製剂的引入以及医疗保健基础设施的改善，预计将实现温和成长。

目录

第一章：引言

第二章执行摘要

第三章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场趋势

第四章：主要考虑因素

  • 临床适应症的流行病学
  • 主要国家的监管状况
  • 新产品发布
  • 产业重大发展动态（合併、收购、合作）
  • 新冠疫情对市场的影响

第五章：2021-2034年全球骨科生技药品市场分析、洞察与预测

  • 市场分析、洞察与预测：按产品类型划分
    • 黏弹性补充剂
    • 骨生长因子
    • 去钙骨基质（DBM）
    • 合成骨替代物
    • 细胞同种异体移植
    • 同种异体移植
    • 其他的
  • 市场分析、洞察与预测：按应用领域划分
    • 脊椎融合手术
    • 颚颜面和牙科护理
    • 软组织修復
    • 重组/骨折手术
    • 其他的
  • 市场分析、洞察与预测：按最终用户划分
    • 医院和门诊手术中心（ASC）
    • 专科诊所
    • 其他的
  • 市场分析、洞察与预测：按地区划分
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美骨科生技药品市场分析、洞察与预测（2021-2034年）

  • 国家
    • 我们
    • 加拿大

第七章：欧洲骨科生技药品市场分析、洞察与预测（2021-2034年）

  • 国家
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪地那维亚
    • 其他欧洲国家

第八章：亚太地区骨科生技药品市场分析、洞察与预测（2021-2034年）

  • 国家
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 东南亚
    • 其他亚太国家

第九章：拉丁美洲骨科生技药品市场分析、洞察与预测（2021-2034年）

  • 国家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲国家

第十章：中东和非洲骨科生技药品市场分析、洞察与预测（2021-2034年）

  • 国家
    • 南非
    • GCC
    • 其他中东和非洲国家

第十一章 竞争分析

  • 全球市占率分析（2025 年）
  • 公司简介
    • Medtronic
    • Zimmer Biomet
    • DePuy Synthes（Johnson & Johnson Services, Inc.）
    • Stryker
    • Anika Therapeutics, Inc.
    • SeaSpine
    • Bioventus
    • RTI Surgical
    • MTF Biologics
    • Arthrex, Inc.
    • Smith & Nephew
Product Code: FBI100173

Growth Factors of orthobiologics Market

The global orthobiologics market is witnessing substantial growth driven by the rising prevalence of bone and musculoskeletal disorders, increasing orthopedic injuries, and the adoption of regenerative medicine. The market was valued at USD 9.7 billion in 2025, projected to reach USD 10.22 billion in 2026, and is expected to grow to USD 15.06 billion by 2034, exhibiting a CAGR of 5.00% during the forecast period. North America dominated the market in 2025, capturing a 47.69% share, owing to rapid adoption of biologics for bone-related injuries, the large patient pool, and a high volume of orthopedic surgeries.

Orthobiologics are products derived from naturally occurring substances in the body, used to enhance the healing of bones, ligaments, tendons, and muscles. They are widely used in orthopedic procedures to repair bone defects and promote tissue regeneration. The increasing use of stem cell-based allografts and other biologics in orthopedic treatments is expected to further fuel market growth.

During the COVID-19 pandemic, the market experienced a temporary decline due to reduced patient visits, reallocation of healthcare resources, and supply chain disruptions. In 2020, the market revenue declined by 10.6%, but recovery began in 2021 with rising patient volumes, vaccination coverage, and resumption of orthopedic surgeries. By 2022, the market returned to pre-pandemic levels, as highlighted by Johnson & Johnson Services, Inc., which reported net sales of USD 94,943 million, including significant contributions from orthopedic products.

Market Trends

A major trend driving the market is the increased use of viscosupplements to delay total knee replacement procedures. Viscosupplements restore the rheological properties of synovial fluid, reduce pain, improve joint function, and promote cartilage regeneration. Studies indicate that treatment with hyaluronic acid injections can delay total knee replacement surgery by over one year, contributing to the growing adoption of viscosupplements.

Market Drivers

The rising incidence of orthopedic injuries, bone fractures, osteoporosis, and sports-related traumas is fueling the demand for orthobiologic products. In the U.S. alone, over 6.8 million patients seek treatment for orthopedic injuries annually. The increasing prevalence of hip and spinal fractures, along with road accidents, is also supporting market expansion.

Another driver is the launch of new orthobiologics products, including allografts, bone growth factors, and synthetic bone substitutes. For example, Royal Biologics launched MAGNUS, a DMSO-free viable cellular bone allograft in 2020, while Biocomposites received CE approval for antibiotic-eluting bone void fillers. Continuous product innovation ensures the availability of advanced solutions for bone repair, enhancing market growth.

Market Restraints

The market faces constraints due to clinical limitations of certain orthobiologics and issues associated with bone morphogenetic proteins (BMPs). Medtronic's INFUSE, a widely used BMP, has been associated with serious side effects such as infections, urinary problems, bone/nerve injury, and potential cancer risk. Adverse tissue reactions, incomplete bone formation, and soft tissue infections with other orthobiologics also limit widespread adoption.

Market Segmentation

By Product Type

  • Viscosupplements held a dominant share of 31.51% in 2026, driven by increasing prevalence of knee osteoarthritis among the aging population.
  • Synthetic bone substitutes are expected to record the highest CAGR due to adoption in developed regions and focus on new product launches.
  • Demineralized Bone Matrix (DBM) and cellular allografts also contribute significantly due to enhanced osteoinductive properties and minimally invasive applications.

By Application

  • Spinal fusion led the market with 31.12% share in 2026, fueled by increasing spinal surgeries globally and approvals for new orthobiologics.
  • Reconstructive & fracture surgeries accounted for the second-largest market share due to rising prevalence of fractures and osteoporosis.

By End-User

  • Hospitals & Ambulatory Surgery Centers (ASCs) dominated with 61.35% market share in 2026, supported by high patient volumes and orthopedic procedures.
  • Specialty clinics are expected to grow significantly due to increasing need for specialized care in orthopedic treatments.

Regional Insights

  • North America: Valued at USD 4.63 billion in 2025, projected to reach USD 4.51 billion in 2026, driven by large patient base and advanced healthcare infrastructure.
  • Europe: Second-largest market, with Germany reaching USD 0.75 billion and the UK USD 0.53 billion by 2026, supported by R&D investments and positive clinical trials.
  • Asia Pacific: Highest CAGR expected due to under-penetration of orthobiologics, large patient pool, and rising bone disease prevalence. Japan, China, and India are projected to reach USD 0.72, 0.55, and 0.3 billion, respectively, by 2026.
  • Latin America & Middle East & Africa: Moderate growth driven by increasing awareness, adoption of novel biologics, and improving healthcare infrastructure.

Competitive Landscape

Key players include Medtronic (Ireland), Zimmer Biomet (U.S.), DePuy Synthes (U.S.), Stryker (U.S.), Anika Therapeutics, Inc. (U.S.), SeaSpine (U.S.), Bioventus (U.S.), RTI Surgical (U.S.), MTF Biologics (U.S.), Arthrex, Inc. (U.S.), and Smith & Nephew (U.K.). Recent developments include:

  • October 2023 - Orthofix Medical launched OsteoCove, a bioactive synthetic graft.
  • June 2023 - Anika Therapeutics received FDA 510(k) clearance for Tactoset Injectable Bone Substitute.
  • March 2023 - LifeNet Health launched ViviGen MIS, a viable bone matrix for MIS spine procedures.

Conclusion

The orthobiologics market is set to grow from USD 9.7 billion in 2025 to USD 15.06 billion by 2034, driven by the increasing prevalence of orthopedic injuries, the adoption of viscosupplements, spinal fusion procedures, and the launch of innovative biologic products. While clinical limitations of certain BMPs and bone graft substitutes may restrain growth, the rising demand for advanced, minimally invasive orthopedic treatments ensures continued market expansion.

Segmentation

By Product Type

  • Viscosupplements
  • Bone Growth Factors
  • Demineralized Bone Matrix (DBM)
  • Synthetic Bone Substitutes
  • Cellular Allograft
  • Others

By Application

  • Spinal Fusion
  • Maxillofacial & Dental
  • Soft Tissue Repair
  • Reconstructive & Fracture Surgery
  • Others

By End-user

  • Hospitals & ASCs
  • Specialty Clinics
  • Others

By Geography

  • North America (By Product Type, By Application, By End-user, and By Country)
    • U.S. (By Application)
    • Canada (By Application)
  • Europe (By Product Type, By Application, By End-user, and By Country/Sub-region)
    • Germany (By Application)
    • U.K. (By Application)
    • France (By Application)
    • Italy (By Application)
    • Scandinavia (By Application)
    • Rest of Europe (By Application)
  • Asia Pacific (By Product Type, By Application, By End-user, and By Country/Sub-region)
    • China (By Application)
    • India (By Application)
    • Japan (By Application)
    • Australia (By Application)
    • Southeast Asia (By Application)
    • Rest of Asia Pacific (By Application)
  • Latin America (By Product Type, By Application, By End-user, and By Country/Sub-region)
    • Brazil (By Application)
    • Mexico (By Application)
    • Rest of Latin America (By Application)
  • Middle East & Africa (By Product Type, By Application, By End-user, and By Country/Sub-region)
    • South Africa (By Application)
    • GCC (By Application)
    • Rest of Middle East & Africa (By Application)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Epidemiology of Clinical Indications
  • 4.2. Regulatory Scenario for Key Countries
  • 4.3. New Product Launches
  • 4.4. Key Industry Developments (Mergers, Acquisitions, and Partnership)
  • 4.5. Impact of COVID-19 on the Market

5. Global Orthobiologics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product Type
    • 5.1.1. Viscosupplements
    • 5.1.2. Bone Growth Factors
    • 5.1.3. Demineralized Bone Matrix (DBM)
    • 5.1.4. Synthetic Bone Substitutes
    • 5.1.5. Cellular Allograft
    • 5.1.6. Allografts
    • 5.1.7. Others
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Spinal Fusion
    • 5.2.2. Maxillofacial & Dental
    • 5.2.3. Soft Tissue Repair
    • 5.2.4. Reconstructive & Fracture Surgery
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By End-user
    • 5.3.1. Hospitals & ASCs
    • 5.3.2. Specialty Clinics
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Orthobiologics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product Type
    • 6.1.1. Viscosupplements
    • 6.1.2. Bone Growth Factors
    • 6.1.3. Demineralized Bone Matrix (DBM)
    • 6.1.4. Synthetic Bone Substitutes
    • 6.1.5. Cellular Allograft
    • 6.1.6. Allografts
    • 6.1.7. Others
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Spinal Fusion
    • 6.2.2. Maxillofacial & Dental
    • 6.2.3. Soft Tissue Repair
    • 6.2.4. Reconstructive & Fracture Surgery
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By End-user
    • 6.3.1. Hospitals & ASCs
    • 6.3.2. Specialty Clinics
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
      • 6.4.1.1. By Application
    • 6.4.2. Canada
      • 6.4.2.1. By Application

7. Europe Orthobiologics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product Type
    • 7.1.1. Viscosupplements
    • 7.1.2. Bone Growth Factors
    • 7.1.3. Demineralized Bone Matrix (DBM)
    • 7.1.4. Synthetic Bone Substitutes
    • 7.1.5. Cellular Allograft
    • 7.1.6. Allografts
    • 7.1.7. Others
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Spinal Fusion
    • 7.2.2. Maxillofacial & Dental
    • 7.2.3. Soft Tissue Repair
    • 7.2.4. Reconstructive & Fracture Surgery
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By End-user
    • 7.3.1. Hospitals & ASCs
    • 7.3.2. Specialty Clinics
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.4.1. Germany
      • 7.4.1.1. By Application
    • 7.4.2. U.K.
      • 7.4.2.1. By Application
    • 7.4.3. France
      • 7.4.3.1. By Application
    • 7.4.4. Italy
      • 7.4.4.1. By Application
    • 7.4.5. Spain
      • 7.4.5.1. By Application
    • 7.4.6. Scandinavia
      • 7.4.6.1. By Application
    • 7.4.7. Rest of Europe
      • 7.4.7.1. By Application

8. Asia Pacific Orthobiologics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product Type
    • 8.1.1. Viscosupplements
    • 8.1.2. Bone Growth Factors
    • 8.1.3. Demineralized Bone Matrix (DBM)
    • 8.1.4. Synthetic Bone Substitutes
    • 8.1.5. Cellular Allograft
    • 8.1.6. Allografts
    • 8.1.7. Others
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Spinal Fusion
    • 8.2.2. Maxillofacial & Dental
    • 8.2.3. Soft Tissue Repair
    • 8.2.4. Reconstructive & Fracture Surgery
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By End-user
    • 8.3.1. Hospitals & ASCs
    • 8.3.2. Specialty Clinics
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.4.1. China
      • 8.4.1.1. By Application
    • 8.4.2. India
      • 8.4.2.1. By Application
    • 8.4.3. Japan
      • 8.4.3.1. By Application
    • 8.4.4. Australia
      • 8.4.4.1. By Application
    • 8.4.5. Southeast Asia
      • 8.4.5.1. By Application
    • 8.4.6. Rest of Asia Pacific
      • 8.4.6.1. By Application

9. Latin America Orthobiologics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product Type
    • 9.1.1. Viscosupplements
    • 9.1.2. Bone Growth Factors
    • 9.1.3. Demineralized Bone Matrix (DBM)
    • 9.1.4. Synthetic Bone Substitutes
    • 9.1.5. Cellular Allograft
    • 9.1.6. Allografts
    • 9.1.7. Others
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Spinal Fusion
    • 9.2.2. Maxillofacial & Dental
    • 9.2.3. Soft Tissue Repair
    • 9.2.4. Reconstructive & Fracture Surgery
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By End-user
    • 9.3.1. Hospitals & ASCs
    • 9.3.2. Specialty Clinics
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 9.4.1. Brazil
      • 9.4.1.1. By Application
    • 9.4.2. Mexico
      • 9.4.2.1. By Application
    • 9.4.3. Rest of Latin America
      • 9.4.3.1. By Application

10. Middle East & Africa Orthobiologics Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product Type
    • 10.1.1. Viscosupplements
    • 10.1.2. Bone Growth Factors
    • 10.1.3. Demineralized Bone Matrix (DBM)
    • 10.1.4. Synthetic Bone Substitutes
    • 10.1.5. Cellular Allograft
    • 10.1.6. Allografts
    • 10.1.7. Others
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Spinal Fusion
    • 10.2.2. Maxillofacial & Dental
    • 10.2.3. Soft Tissue Repair
    • 10.2.4. Reconstructive & Fracture Surgery
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By End-user
    • 10.3.1. Hospitals & ASCs
    • 10.3.2. Specialty Clinics
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 10.4.1. South Africa
      • 10.4.1.1. By Application
    • 10.4.2. GCC
      • 10.4.2.1. By Application
    • 10.4.3. Rest of Middle East & Africa
      • 10.4.3.1. By Application

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Medtronic
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Zimmer Biomet
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. DePuy Synthes (Johnson & Johnson Services, Inc.)
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Stryker
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Anika Therapeutics, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. SeaSpine
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Bioventus
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. RTI Surgical
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. MTF Biologics
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Arthrex, Inc.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)
    • 11.2.11. Smith & Nephew
      • 11.2.11.1. Overview
      • 11.2.11.2. Products
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Orthobiologics Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 2: Global Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 3: Global Orthobiologics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 4: Global Orthobiologics Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America Orthobiologics Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 6: North America Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 7: North America Orthobiologics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 8: North America Orthobiologics Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: U.S. Orthobiologics Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 10: Canada Orthobiologics Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 11: Europe Orthobiologics Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 12: Europe Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 13: Europe Orthobiologics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 14: Europe Orthobiologics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 15: Germany Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 16: U.K. Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 17: France Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 18: Italy Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 19: Spain Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 20: Scandinavia Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 21: Rest of Europe Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 22: Asia Pacific Orthobiologics Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 23: Asia Pacific Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 24: Asia Pacific Orthobiologics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 25: Asia Pacific Orthobiologics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: China Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 27: India Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 28: Japan Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 29: Australia Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 30: Southeast Asia Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 31: Rest of Asia Pacific Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 32: Latin America Orthobiologics Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 33: Latin America Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 34: Latin America Orthobiologics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 35: Latin America Orthobiologics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 36: Brazil Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 37: Mexico Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 38: Rest of Latin America Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 39: Middle East & Africa Orthobiologics Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 40: Middle East & Africa Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 41: Middle East & Africa Orthobiologics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 42: Middle East & Africa Orthobiologics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 43: South Africa Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 44: GCC Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 45: Rest of Middle East & Africa Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034

List of Figures

  • Figure 1: Global Orthobiologics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Orthobiologics Market Value Share (%), by Product Type, 2025 & 2034
  • Figure 3: Global Orthobiologics Market Value Share (%), by Application, 2025 & 2034
  • Figure 4: Global Orthobiologics Market Value Share (%), by End-user, 2025 & 2034
  • Figure 5: Global Orthobiologics Market Value (USD billion), by Region, 2025 & 2034
  • Figure 6: North America Orthobiologics Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 7: North America Orthobiologics Market Value Share (%), by Product Type, 2025
  • Figure 8: North America Orthobiologics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 9: North America Orthobiologics Market Value Share (%), by Application, 2025
  • Figure 10: North America Orthobiologics Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 11: North America Orthobiologics Market Value Share (%), by End-user, 2025
  • Figure 12: North America Orthobiologics Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Orthobiologics Market Value Share (%), By Country, 2025
  • Figure 14: Europe Orthobiologics Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 15: Europe Orthobiologics Market Value Share (%), by Product Type, 2025
  • Figure 16: Europe Orthobiologics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 17: Europe Orthobiologics Market Value Share (%), by Application, 2025
  • Figure 18: Europe Orthobiologics Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 19: Europe Orthobiologics Market Value Share (%), by End-user, 2025
  • Figure 20: Europe Orthobiologics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Orthobiologics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Orthobiologics Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 23: Asia Pacific Orthobiologics Market Value Share (%), by Product Type, 2025
  • Figure 24: Asia Pacific Orthobiologics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 25: Asia Pacific Orthobiologics Market Value Share (%), by Application, 2025
  • Figure 26: Asia Pacific Orthobiologics Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 27: Asia Pacific Orthobiologics Market Value Share (%), by End-user, 2025
  • Figure 28: Asia Pacific Orthobiologics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Orthobiologics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America Orthobiologics Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 31: Latin America Orthobiologics Market Value Share (%), by Product Type, 2025
  • Figure 32: Latin America Orthobiologics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 33: Latin America Orthobiologics Market Value Share (%), by Application, 2025
  • Figure 34: Latin America Orthobiologics Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 35: Latin America Orthobiologics Market Value Share (%), by End-user, 2025
  • Figure 36: Latin America Orthobiologics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Orthobiologics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Orthobiologics Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 39: Middle East & Africa Orthobiologics Market Value Share (%), by Product Type, 2025
  • Figure 40: Middle East & Africa Orthobiologics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 41: Middle East & Africa Orthobiologics Market Value Share (%), by Application, 2025
  • Figure 42: Middle East & Africa Orthobiologics Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 43: Middle East & Africa Orthobiologics Market Value Share (%), by End-user, 2025
  • Figure 44: Middle East & Africa Orthobiologics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Orthobiologics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global Orthobiologics Market Share (%), By Company, 2025